Every 8-K that Aeluma, Inc. (ALMU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALMU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMU filings page.
Aeluma, Inc. (ALMU) approved and adopted amended and restated bylaws on September 29, 2026, reducing the quorum required to hold a stockholder meeting from a majority to one-third (1/3) of the voting power of its issued and outstanding capital stock entitled to vote.
Aeluma, Inc. (ALMU) reported fourth-quarter and full fiscal year 2026 results for the year ended June 30, 2026. Revenue was $4.46 million, slightly below $4.67 million a year earlier, while the GAAP net loss widened to $9.16 million from $3.02 million, reflecting significantly higher R&D and general and administrative spending.
Adjusted EBITDA declined to -$5.22 million from $0.19 million. Liquidity strengthened, with cash and cash equivalents at $56.01 million, driven mainly by a $43.48 million public offering and warrant exercises, lifting stockholders’ equity to $56.93 million and book value per share to $3.06.
The company highlighted a signed letter of intent with the U.S. Department of Commerce CHIPS R&D Office for up to $30 million in potential funding, an expanded wafer-capacity agreement with Sumitomo Chemical Advanced Technologies, and a strategic shift from early-stage government R&D contracts toward AI datacom commercialization. Aeluma set November 19, 2026 as its next annual stockholder meeting date, with stockholder proposal and nomination notices due by September 26, 2026.
Aeluma, Inc. entered a CHIPS and Science Act Letter of Intent with the U.S. Department of Commerce’s CHIPS Research & Development Office for up to $30 million in proposed funding. The LOI supports R&D and commercialization of Aeluma’s scalable non-InP photonics manufacturing platform for AI and advanced computing applications.
The potential award is subject to further due diligence, required U.S. government approvals, and execution of definitive award documents. The LOI contemplates a portion of funds paid up front and the balance on a milestone-based structure, with Aeluma issuing unregistered equity securities to Commerce with an aggregate value equal to any final award.
Aeluma, Inc. furnished an updated investor presentation outlining its semiconductor photonics strategy and business position. The company highlights its Indium Gallium Arsenide (InGaAs) and large‑diameter wafer technology aimed at shortwave infrared sensing, AI infrastructure, datacom, defense, and quantum markets.
The deck notes recurring R&D revenue of $4 FY25, cash of about $37 as of 3/31/26, around 36 issued and pending patents, and more than 20 customer engagements, including sampling, NRE work and initial sales. Aeluma reports a 27-person team, capital‑light manufacturing that relies on partners, ISO 9001:2015 certification, and about 12k sq. ft. of facilities in Goleta, California with materials production and test capabilities.
The presentation frames large market opportunities in mobile and consumer SWIR sensors and AI data-center optical interconnects, citing substantial hyperscaler data-center capital spending and an industry shortage of indium phosphide substrates and fab capacity.
Aeluma, Inc. reported third quarter fiscal 2026 results showing modest revenue and ongoing investment-driven losses. Revenue for the three months ended March 31, 2026 was $1,222 thousand, while the company recorded a GAAP net loss of $1,800 thousand, or $(0.10) per basic and diluted share. For the nine-month period, revenue reached $3,879 thousand with a net loss of $5,146 thousand.
On a non-GAAP basis, which excludes items such as stock-based compensation and certain non-cash charges, Aeluma reported a third quarter net loss of $701 thousand and adjusted EBITDA of $(911) thousand. The company ended March 31, 2026 with $37,780 thousand in cash and cash equivalents, supporting its manufacturing and commercialization priorities.
Aeluma narrowed full fiscal 2026 revenue guidance to $4.2 million to $4.6 million, from a prior range of $4.0 million to $6.0 million, citing delays in contract execution related to government shutdowns and other factors. Management highlighted six new development engagements totaling $5 million and emphasized growing interest tied to AI data center and photonics demand.
Aeluma, Inc. entered into a Sales Agreement that allows it to issue and sell up to $50.0 million of its common stock from time to time through a group of sales agents. Any shares will be offered under an effective Form S-3 shelf registration statement.
Sales, if made, will occur as ordinary brokers’ transactions on the Nasdaq Capital Market at market prices or as otherwise agreed with the agents. Neither Aeluma nor the agents are obligated to sell or purchase shares, and either party can terminate the agreement with five business days’ written notice.
Aeluma, Inc. reported financial results for its second quarter of fiscal 2026, for the period ended December 31, 2025. Revenue for the quarter was $1.27 million, compared with $1.39 million in the prior quarter and $1.61 million a year earlier, while the company posted a GAAP net loss of $1.85 million (or $0.11 per share).
For the first six months of fiscal 2026, revenue totaled $2.66 million and the GAAP net loss was $3.35 million. On a non-GAAP basis, which excludes stock-based compensation, certain financing-related items, and other adjustments, Aeluma reported a second-quarter net loss of $0.80 million and adjusted EBITDA of $(0.92) million.
The company emphasized progress toward commercialization, citing increasing customer engagements and initial sales orders, and reaffirmed its full fiscal 2026 revenue outlook in the range of $4.0 million to $6.0 million. Aeluma ended the quarter with $38.57 million in cash and cash equivalents, supporting ongoing research, development, and go-to-market activities.
Aeluma, Inc. reported the results of its 2025 Annual General Meeting of shareholders. The meeting had a quorum, with 9,892,101 shares of common stock present or represented by proxy, representing 55.4% of the voting power entitled to vote.
Shareholders re-elected Steven P. DenBaars and John Paglia to the Board of Directors by plurality of the votes cast. A second proposal also passed, receiving 9,822,341 votes For, 57,925 Against, and 11,835 Abstain. The filing notes that broker non-votes are included only for purposes of determining whether a quorum is present.
Aeluma, Inc. furnished an 8‑K announcing it issued a press release with financial results for the first quarter ended September 30, 2025. The release accompanies the company’s Form 10‑Q filed the same day and is included as Exhibit 99.1. The information under Item 2.02 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated.
Aeluma, Inc. (ALMU) filed an 8-K under Item 8.01 to furnish its new investor PowerPoint presentation as Exhibit 99.1. The company also included the standard legend stating the report and exhibit do not constitute an offer to sell or a solicitation to buy securities in any jurisdiction prior to proper registration or qualification. The filing lists the company’s common stock trading on Nasdaq under the symbol ALMU.
Aeluma, Inc. reported that director Steven DenBaars has terminated a previously adopted Rule 10b5-1 trading plan. The plan, adopted on June 23, 2025, had authorized the potential sale of up to 130,000 shares of Aeluma common stock between October 6, 2025 and May 6, 2026 under preset price and formula conditions. On September 16, 2025, the plan was terminated, and the company stated that no sales were or will be made under this 10b5-1 plan.
Aeluma, Inc. (ALMU) filed an 8-K reporting execution of an Underwriting Agreement dated September 17, 2025 with Craig-Hallum Capital Group LLC acting as representative of the underwriters for shares of the company’s common stock listed on The Nasdaq Stock Market LLC. The filing includes a legal opinion and consent from Hunter Taubman Fischer & Li LLC and attaches two press releases dated September 17, 2025 and September 18, 2025. The document is signed by Jonathan Klamkin, President and CEO, on September 19, 2025. The filing lists the company ticker as ALMU but does not disclose offering size, price, net proceeds, use of proceeds, or other economic terms within the provided text.
Aeluma, Inc. filed a current report to note that it released its financial results for the fourth quarter ended June 30, 2025. The company issued a press release on September 9, 2025 describing its results and overall financial condition for that quarter. That press release is attached to the report as an exhibit and is described as furnished rather than filed, which limits how it is treated under securities laws.
Aeluma, Inc. appointed Christopher Stewart as full-time Chief Financial Officer and Principal Accounting Officer effective August 4, 2025. Stewart replaces interim CFO James Seo and brings prior public-company CFO experience at LeddarTech and Bionano Genomics and senior financial leadership roles at Maxwell Technologies, Entropic Communications and Intel. The company will enter into a standard indemnification agreement with him.
Stewart's compensation includes an annual salary of $300,000, an option to purchase 110,000 shares under the 2021 Stock Incentive Plan and 55,000 restricted stock units subject to the Plan. The employment agreement is attached as Exhibit 10.1 and a press release announcing the appointment is filed as Exhibit 99.1. The filing states no family relationships or transactions requiring Item 404 disclosure.